Hero doctor's devastating health update
Professor Scolyer, 58, was diagnosed with the aggressive and incurable glioblastoma in 2023 and initially given just eight months to live. However, after undergoing experimental immunotherapy based on melanoma research, his cancer remained at bay for 18 months.
In a social media post on Monday, Professor Scolyer confirmed a recent MRI scan had shown further progression of the tumour on the left side of his brain. Professor Georgina Long AO & Professor Richard Scolyer AO (NSW) at the 2024 Australian of the year awards at the National Arboretum Canberra. NCA NewsWire / Martin Ollman Credit: News Corp Australia
'While this may not be the best direction to be heading with my changes, amazingly (to me), I still seem keen to keep living, loving and having fun, whenever possible,' he wrote on social media.
'I feel like there are quite a few people on my team (including my family & friends) and they make me happy and proud.'
The prominent cancer researcher, jointly named Australian of the Year in 2024 alongside fellow Melanoma Institute Australia co-director Professor Georgina Long, has remained remarkably candid and optimistic throughout his treatment journey. Professor Scolyer credited his friends and family, saying they make him 'happy and proud'. Facebook Credit: Supplied
In February, Professor Scolyer announced the cancer had returned, prompting him to undergo surgery in March to remove as much of the tumour as possible.
He later explained that while the procedure successfully removed a significant portion of the mass, 'little tentacles' remained and would require additional treatment to 'mop up' the remaining cancer cells.
'Depending on what the scan shows … that will help choose what are the next forms of therapy that I can have to see where we need to go from here,' he said at the time. A recent MRI scan showed, in the left side of his brain, further progress of his tumour. Facebook Credit: Supplied
He also acknowledged the emotional and physical toll of ongoing treatment, admitting he had been feeling 'a little up and down' due to side effects, though he continued to cherish time spent with his wife Katie and their children.
'Sometimes I'm happy to have fun, but some of the therapies have knocked me around a bit, so I can't do some of the things I love doing,' he said.
'I'm still having a fun time at home with my kids, they've been very kind, as well as my beautiful wife Katie has, who's been using her incredible intellect to help me speak to different doctors about various options that are available.'
Professor Scolyer said he expects to undergo another operation and remains hopeful about future treatments.
'Fingers crossed this operation isn't so bad and we can move forward with the next form of therapy and hopefully push things along faster to try and get things open up for many, many patients who have got glioblastoma,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Perth Now
a day ago
- Perth Now
Healthcare giant's $21bn loss sinks ASX200
Australia's sharemarket snapped a six-day winning streak after pharmaceutical giant CSL had its worst day of trading on record after announcing a disappointing earnings update. The ASX 200 index dropped 63.10 points or 0.70 per cent to 8,896.20 while the broader All Ordinaries fell 59.70 points or 0.65 per cent to 9,173.80 The Australian dollar slipped 0.14 per cent to 64.85 US cents. Seven of the 11 sectors ended higher but a slump in the healthcare sector led to the market downturn. The ASX 200 slumped on CSL's results. NewsWire / Max Mason-Hubers Credit: News Corp Australia Healthcare stocks fell 8.73 per cent, led by CSL shares which slumped 16.89 to $225.50 its biggest ever one day fall, despite reporting underlying profits were up 14 per cent to $3.3bn. This was a fall of around $21bn in market cap. Shares plunged in the healthcare giant after it announced it would cut 3000 global roles costing $770m initially before helping the business save $500m-$550m over three years. CSL also announced its intention to demerge its influenza prevention vaccines-focused unit known as Seqirus into a separate ASX-listed business in 2026. It will also combine the commercial and medical operations of its core blood plasma and iron deficiency businesses into one unit. eToro market analyst Josh Gilbert said while the restructuring comes with a sizeable one off cost, the move is expected to sharpen the group's focus on its high-growth plasma and kidney care business. 'For investors, the view here is that CSL is trying to create a clearer business structure and improve investor returns. However, markets hate uncertainty, and this shake-up brings plenty of it,' he said. 'These are huge changes that come with execution risk, and in my view, the market will react poorly to the news short term.' Overall seven of the 11 sectors finished higher. NewsWire / Max Mason-Hubers Credit: News Corp Australia Australia's second-biggest company BHP jumped 1.57 per cent to $42.12 after the business delivered its latest financial update. The company reported underlying profits of $US10.2bn ($A15.7bn), a 26 per cent fall compared with last year. Revenues came in at $US51.3bn ($A79bn), an 8 per cent fall in 2024. Despite falls in revenue and earnings, chief executive Mike Henry called the results 'a strong performance'. 'FY25 was another strong year for BHP, marked by record production, continued sector-leading margins and disciplined capital allocation,' he said. 'Safety remains our highest priority and we achieved year-on-year improvements across key metrics.' Shares in iron ore rivals Rio Tinto and Fortescue were down 0.22 and 0.15 per cent respectively. Financials were a brighter spot, with all four banks gaining. CBA added 0.51 per cent to $171.05, Westpac gained 0.65 per cent to $37.31, NAB jumped 0.77 per cent to $40.54 and ANZ finished 0.61 per cent higher to $32.77. In company news, Seek was one of strongest performers on the ASX 200 after it announced an increase in revenue despite fewer job ads, leading to a 7.99 per cent bounce to $27.72. Australia's largest manufacturer and distributor of 4x4 accessories ARB shares marched 8.55 per cent higher to $39.49 after the business told the market sales revenue was up 5.3 per cent to $729.9m, while net profits after tax were down 5 per cent to $97.5m. Judo Capital also eked out a gain of 0.29 per cent to $1.75 after full-year profits were up 24 per cent to $86.4m, on the back of a lift to its all important net interest margin. Reliance Worldwide shares fell 6.74 per cent to $4.29 despite the business announcing sales were up 5.5 per cent and reported net earnings after tax jumped 13.5 per cent to $US125m ($192m).
Sydney Morning Herald
3 days ago
- Sydney Morning Herald
They built a billion-dollar start-up from their garage. Now they're going again
They created one of Australia's most valuable technology start-ups in a Brisbane garage – Go1 – an education platform most recently valued at $3 billion. Now, Go1 co-founders Vu Tran and Andrew Barnes and entrepreneur Gopi Sara have unveiled their next company, OneMRI, which they say is Australia's first and only national provider of whole-body MRI scans. They say it has a similarly sized growth opportunity to their prior start-up. Existing Go1 investors and executives as well as clinicians and radiologists have poured a collective $2.5 million into OneMRI in a seed funding round to fuel its expansion nationally, amid rising demand from 'health curious' individuals who want a full-body scan but don't know where to turn. In between running start-ups, Tran works as a general practitioner, and he said in an interview that OneMRI had been born out of a frustration in not knowing how or where to refer patients for MRI scans. 'It's not covered by Medicare, and no one is catering for it,' Tran said. 'There are all these machines out there that are underutilised, and there are a lot of people out there who want MRI scans. We're that bridge. 'I've been a GP for 10 years and patients are more interested in wellness and their healthcare than they've ever been. And unfortunately, there's a lot of focus in the Medicare system on sick care, not necessarily health care.' Barnes spent nearly a decade as Go1 CEO before stepping down in August last year, though he still spends some time working at the company and he remains on its board. He started Go1 with Tran, a schoolmate, and Chris Hood in 2015 and that same year they were accepted into the Silicon Valley start-up accelerator Y Combinator. More than 10,000 organisations now use Go1 for staff training, and 50 million registered users have completed courses on the platform. Go1 executives are reported to be mulling an IPO and the company has an ambition to reach 1 billion learners globally.
The Age
3 days ago
- The Age
They built a billion-dollar start-up from their garage. Now they're going again
They created one of Australia's most valuable technology start-ups in a Brisbane garage – Go1 – an education platform most recently valued at $3 billion. Now, Go1 co-founders Vu Tran and Andrew Barnes and entrepreneur Gopi Sara have unveiled their next company, OneMRI, which they say is Australia's first and only national provider of whole-body MRI scans. They say it has a similarly sized growth opportunity to their prior start-up. Existing Go1 investors and executives as well as clinicians and radiologists have poured a collective $2.5 million into OneMRI in a seed funding round to fuel its expansion nationally, amid rising demand from 'health curious' individuals who want a full-body scan but don't know where to turn. In between running start-ups, Tran works as a general practitioner, and he said in an interview that OneMRI had been born out of a frustration in not knowing how or where to refer patients for MRI scans. 'It's not covered by Medicare, and no one is catering for it,' Tran said. 'There are all these machines out there that are underutilised, and there are a lot of people out there who want MRI scans. We're that bridge. 'I've been a GP for 10 years and patients are more interested in wellness and their healthcare than they've ever been. And unfortunately, there's a lot of focus in the Medicare system on sick care, not necessarily health care.' Barnes spent nearly a decade as Go1 CEO before stepping down in August last year, though he still spends some time working at the company and he remains on its board. He started Go1 with Tran, a schoolmate, and Chris Hood in 2015 and that same year they were accepted into the Silicon Valley start-up accelerator Y Combinator. More than 10,000 organisations now use Go1 for staff training, and 50 million registered users have completed courses on the platform. Go1 executives are reported to be mulling an IPO and the company has an ambition to reach 1 billion learners globally.
